Over 80% of cancer patients fail to respond to immunotherapy because current approaches target only a single pathway—missing the complex, multi-pathway interactions between immune cells within tumors.
At Voyant, we’ve developed the first AI-guided, spatially differentiated microscopy platform to reveal these hidden immune interactions that drive resistance to treatment across multiple cancer types.
Using patient-derived tumor resections, our platform identifies novel immune cell interaction targets with clinical relevance. One such discovery—a novel 3-way immune interaction linked to PD-1 resistance—was recently published in Nature.
We’re now advancing a novel therapeutic in a $100B+ market and are currently raising a $3M pre-seed to complete ex vivo studies and expand our immune cell interaction atlas.
Company Details
- Employees
- 8
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://voyant-bio.com
Voyant Bio Questions
Voyant Bio's website is https://voyant-bio.com
Voyant Bio's LinkedIn profile is https://www.linkedin.com/company/voyantbio
Voyant Bio has
8 employees.
View email and phone details for 8
employees at Voyant Bio.
Voyant Bio's industry is
Biotechnology Research
Voyant Bio's top competitors are
Hebbian Bio,
Misogi Labs,
Esya Labs,
Modernvivo,
Simurx, Inc.,
Potato,
Augment Biologics,
Inapill,
Imyoo,
Ubiquitx, Inc..
Voyant Bio's categories are Biotechnology Research
Voyant Bio's founding year is 2023
